


**Product Name** : BMS-955176  
**Cat. No.** : PC-61452  
**CAS No.** : 1392312-45-6  
**Molecular Formula** : C<sub>42</sub>H<sub>62</sub>N<sub>2</sub>O<sub>4</sub>S  
**Molecular Weight** : 691.03  
**Target** : HIV  
**Solubility** : 10 mM in DMSO



## Biological Activity

BMS-955176 (GSK-3532795) is a second-generation **HIV-1 maturation** inhibitor that exhibits potent activity (EC<sub>50</sub>=3.9±3.4 nM) against a library (n=87) of gag/pr recombinant viruses.

BMS-955176 exhibits median EC<sub>50</sub> of 21 nM toward a library of subtype B clinical isolates assayed in PBMCs.

BMS-955176 inhibits HIV-1 protease cleavage at the CA/SP1 junction within Gag in VLPs and in HIV-1-infected cells, and binds reversibly and with high affinity to assembled Gag in purified HIV-1 VLPs.

BMS-955176 has a greatly improved preclinical profile compared to that of Bevirimat.

## References

Nowicka-Sans B, et al. *Antimicrob Agents Chemother.* 2016 Jun 20;60(7):3956-69.

Regueiro-Ren A, et al. *ACS Med Chem Lett.* 2016 Apr 22;7(6):568-72.

Lin Z, et al. *PLoS Pathog.* 2016 Nov 28;12(11):e1005990.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com